Adela Cimic

Adela Cimic

Auto-generated profile, based on publicly available information

Adela Cimic

Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, United States

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

30 May 2019 in Cancer Cytopathology
Verified
Journal Article
Closed access
PDF file
ACAdela Cimic
Adela Cimic
TWTimothy J. Wilkin
Timothy J. Wilkin
JHJonas J. Heymann
Jonas J. Heymann
SASusan Alperstein
Susan Alperstein
GEGrant Ellsworth
Grant Ellsworth
MSMomin T. Siddiqui
Momin T. Siddiqui

30 May 2020 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
PDF file
ICIjeuru Chikeka
Ijeuru Chikeka
SSSimon Sung
Simon Sung
PTPatricia Tiscornia‐Wasserman
Patricia Tiscornia‐Wasserman
ACAdela Cimic
Adela Cimic

24 May 2019 in Cytojournal
Verified
Journal Article
Open access
PDF file
ACAdela Cimic
Adela Cimic
MMMaria Mironova
Maria Mironova
FKFady Khoury-Collado
Fady Khoury-Collado
ZSZiyan Salih
Ziyan Salih
Background: The ovaries can be the site for various primary tumors and also the presenting site of metastatic disease. Quick and correct intraoperative diagnosis is crucial for the patient's further management. The aim of this study was to demonstrate the advantages of the combined diagnostic method – ovarian frozen sections in conjunction with cytologic smears. Methods: From June 2016 to June 2017, we prospectively prepared additional two cytologic smears with Diff-Quik stain on ovarian frozen sections comprised of two hematoxylin and eosin sections. For quality assurance purposes, we compared the results of frozen section discrepancies and deferrals with those that of the previous year from June 2015 to June 2016. Results: With the introduction of cytologic smears to ovarian frozen sections, the number of discrepancies and deferrals combined decreased from 13.75% to 7.85%. The most benefit of smears was observed in primary ovarian malignancies. Conclusions: In the setting where all the members of the pathology group render cytologic evaluations routinely, smears play an important complementary role.

1 January 2020 in Journal of Pathology Informatics
Verified
Journal Article
Open access
ACAdela Cimic
Adela Cimic
MMMaria Mironova
Maria Mironova
SKScarlett Karakash
Scarlett Karakash
SSSahussapont Joseph Sirintrapun
Sahussapont Joseph Sirintrapun
Accurate pathologic assessment in placental pathology is mostly dependent on a complete clinical history provided by a clinical team. However, often, the necessary clinical information is lacking, and electronic order sets (EOSs), if implemented correctly, create an opportunity for entering consistent and accurate clinical data. In this viewpoint piece, we describe a framework for synoptic EOS in placental pathology. We outline the necessary data and create optional clinical data that get entered as a dropdown menu of free text. While EOSs are the best way to approach and diagnose placenta and other nonneoplastic pathologic specimens, the barriers for implementation include paper requisitions and a cultural mindset resistance. The aspiration for our synoptic EOS is to become an effective tool for communication between proceduralists and pathologists for proper diagnosis of placental specimens. Through our EOS, the appropriate and complete clinical context is conveyed from the clinical teams to the pathologist. The pathologist can easily and rapidly extract the necessary information to render an accurate and precise diagnosis. The captured data likewise become a valuable research resource.

1 October 2019 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
Semir VranicSemir Vranic
Semir Vranic
DAD. Arguello
D. Arguello
ECE. Contreras
E. Contreras
ACA. Cimic
A. Cimic
ZGZ. Gatalica
Z. Gatalica
Neuroendocrine carcinoma of the uterine cervix (NEC) is a rare cervical malignancy, accounting for 0.9% of all cervical carcinomas. Cervical NEC is a high-grade cancer with an aggressive clinical course and poor outcome. Given that no target therapy has been approved yet for NEC, we explored novel targetable biomarkers in a large cohort of NEC of the cervix. Sixty-two NEC of the cervix were profiled for biomarkers of targeted therapy including antibody-drug conjugates (DLL3, TROP-2, and FOLR1), tropomyosin receptor kinases (NTRK1/2/3 gene fusions), and immune checkpoint inhibitors (PD-L1, TMB, and MSI) using immunohistochemistry and DNA/RNA next-generation sequencing assays. The study included 36 primary and 26 metastatic cervical NEC. The mean patient’s age was 43.6 years (range, 24-82 years). DLL3 expression was observed in 81% of the cases with 49% of cases expressing diffusely (≥50% of positive cancer cells) DLL3 protein. DLL3 expression was inversely correlated with commonly observed mutations: PIK3CA (7/47) (p = 0.018) and PTEN mutations (5/40) (p = 0.006). Other frequently seen mutations (TP53 17%, KRAS 11% and CTTNB1 5%) were not associated with DLL3 expression. PD-L1 expression, high TMB and MSI-H were seen in single cases. Although NTRK protein expression was observed in 21% of the cases, none of these had confirmatory NTRK gene fusions. TROP-2 and FOLR1 were negative in all tested cases. DLL3 protein and PIK3CA/PTEN pathway genes may be potential therapeutic targets for a substantial proportion of the patients NEC of the cervix. Based on I-O biomarkers status, the patients with cervical NEC are less likely to benefit from immune checkpoint inhibitors. The authors. Has not received any funding. D. Arguello: Full / Part-time employment: Caris Life Sciences. E. Contreras: Full / Part-time employment: Caris Life Sciences. Z. Gatalica: Full / Part-time employment: Caris Life Sciences. All other authors have declared no conflicts of interest.